Tecentriq meets endpoints in Phase III for extensive-stage SCLC

Roche (SIX:ROG; OTCQX:RHHBY) said first-line treatment with Tecentriq atezolizumab plus chemotherapy met the co-primary endpoints of improving overall survival (OS) and progression-free

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE